Deltagen, Inc. (Pink Sheets: DGEN), a provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended March 31, 2013.
Revenues: The Company’s consolidated revenues for the three months ended March 31, 2013 totaled $0.194 million. The revenues in the first quarter of 2013 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOneTM program.
Help employers find you! Check out all the jobs and post your resume.
